Log in to search using one of your social media accounts:

This page shows you the latest news items in this category. This is page number 4.

J & J arthritis drug goes up against Humira, with mixed results
(Reuters) - Johnson& Johnson said its experimental sirukumab treatment for rheumatoid arthritis showed mixed results against AbbVie Inc's top-selling Humira in a large trial. (Source: Reuters: Health)
Source: Reuters: Health - November 12, 2016 Category: Consumer Health News Tags: healthNews Source Type: news

Mayo Clinic research sheds light on why some rheumatoid arthritis patients respond poorly to biologics
(Mayo Clinic) A Mayo Clinic study is shedding light on why some rheumatoid arthritis patients respond poorly when treated with tumor necrosis factor inhibitors, part of a class of drugs called biologics. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - November 12, 2016 Category: Global & Universal Source Type: news

Staying on dmards through surgery does not increase post-op infection risk
(American College of Rheumatology) Rheumatoid arthritis patients who keep using their disease-modifying antirheumatic drugs prior to surgery do not face an increased risk of infection after their procedures, according to new research findings presented this week at the 2016 ACR/ARHP Annual Meeting in Washington. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - November 12, 2016 Category: Global & Universal Source Type: news

First-line therapy with rituximab may lower mortality risk in RA patients with lung conditions
(American College of Rheumatology) Patients with rheumatoid arthritis who also have lung involvement often have increased mortality, but first-line therapy with rituximab may help them live longer when compared with the use of TNF inhibitors , according to new research findings presented this week at the 2016 ACR/ARHP Annual Meeting in Washington. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - November 12, 2016 Category: Global & Universal Source Type: news

Three gene sets could predict response to rheumatoid arthritis therapies
(American College of Rheumatology) Three gene expression signatures can help rheumatologists predict which patients are more likely to respond to tumor necrosis factor inhibitors (TNFi) or B-cell depletion therapies in patients with moderate to severe rheumatoid arthritis, according to new research findings presented this week at the American College of Rheumatology Annual Scientific Meeting in Washington. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - November 12, 2016 Category: Biology Source Type: news

Monocyte gene expression signatures predict how ra patients respond to anti-TNF therapy
(American College of Rheumatology) Distinct gene expression signatures in rheumatoid arthritis patients could help rheumatologists predict how these individuals will respond to tumor necrosis factor inhibitors, and may one day enable a more personalized approach to RA therapy, according to new research findings presented this week at the 2016 ACR/ARHP Annual Meeting in Washington. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - November 12, 2016 Category: Biology Source Type: news

Blood Test Can Help Identify Early-Stage Arthritis Blood Test Can Help Identify Early-Stage Arthritis
A blood test that quantifies fragments of damaged protein can help diagnose early-stage osteoarthritis (OA), rheumatoid arthritis (RA) and other types of inflammatory joint disease, new findings show.Reuters Health Information (Source: Medscape Orthopaedics Headlines)
Source: Medscape Orthopaedics Headlines - November 9, 2016 Category: Orthopaedics Tags: Pathology & Lab Medicine News Source Type: news

US as a Marker of Early Response to Abatacept in RA US as a Marker of Early Response to Abatacept in RA
Ultrasound can play an important role in assessing the early efficacy of abatacept among biologic-naive rheumatoid arthritis patients.Annals of the Rheumatic Diseases (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 9, 2016 Category: Consumer Health News Tags: Rheumatology Journal Article Source Type: news

AbbVie exhibit shortlisted at Experience Design & Technology Awards
The Experience Design & Technology Awards, in association with Event Marketer, are judged by client-side marketers, design authors and professors, and were created to recognise the brands and partners that create the best designed experiences and engagements. Ashfield Meetings & Events | Exhibits designed and built the exhibit in partnership with their client, AbbVie. It showcased their product HUMIRA® at the Annual European Congress of Rheumatology (EULAR) in 2016. HUMIRA® is a leading treatment for conditions such as rheumatoid arthritis, axial spondyloarthritis and psoriatic arthritis. The booth design created...
Source: Ashfield Healthcare News - November 8, 2016 Category: Pharmaceuticals Authors: Ewan Jamieson Tags: Ashfield Source Type: news

Early rheumatoid arthritis treatment may prevent rapid bone loss
Ryan MaassNYON, Switzerland, Nov. 7 (UPI) -- Early and aggressive treatment for rheumatoid arthritis may help protect against progressive bone loss, researchers concluded in a recent study. (Source: Health News - UPI.com)
Source: Health News - UPI.com - November 7, 2016 Category: Consumer Health News Source Type: news

Biologic therapies for rheumatoid arthritis may protect against rapid bone loss
(International Osteoporosis Foundation) A new review by the International Osteoporosis Foundation (IOF) Chronic Inflammation and Bone Structure (CIBS) Working Group concludes that early and aggressive treatment of Rheumatoid Arthritis (RA) with biologic drugs, specifically biological disease-modifying anti-rheumatic drugs (DMARDs), may be most effective in halting progressive bone loss in patients with RA. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - November 7, 2016 Category: Global & Universal Source Type: news

Eli Lilly and Incyte report positive data from Phase III RA-BEACON trial of baricitinib to treat rheumatoid arthritis
Eli Lilly and Company and Incyte Corporation announced that new data from RA-BEACON, a phase 3 study of baricitinib in the treatment of moderate-to-severe rheumatoid arthritis (RA), indicated baricitinib had demonstrated significant improvement in pa … (Source: Drug Development Technology)
Source: Drug Development Technology - November 4, 2016 Category: Pharmaceuticals Source Type: news

South Korea Celltrion to expand R & D investment for original drugs
INCHEON, South Korea (Reuters) - South Korea's drugmaker Celltrion Inc, whose copy of blockbuster rheumatoid arthritis drug Remicade is about to hit the U.S. market, aims to expand R&D spending five-fold to one trillion won ($876.24 million) in the next two or three years to help bolster a pipeline of original drugs, its co-CEO said. (Source: Reuters: Health)
Source: Reuters: Health - November 2, 2016 Category: Consumer Health News Tags: healthNews Source Type: news

U.S. FDA Spurns Sanofi, Regeneron Arthritis Drug Over Manufacturing Lapse U.S. FDA Spurns Sanofi, Regeneron Arthritis Drug Over Manufacturing Lapse
Sanofi SA and Regeneron Pharmaceuticals Inc on Friday said U.S. regulators had declined to approve their experimental treatment for rheumatoid arthritis because of manufacturing deficiencies.Reuters Health Information (Source: Medscape Orthopaedics Headlines)
Source: Medscape Orthopaedics Headlines - October 31, 2016 Category: Orthopaedics Tags: Pharmacist News Source Type: news

Antares Pharma Appoints Fred M. Powell, Senior Vice President and Chief Financial Officer
EWING, N.J., Oct. 31, 2016 -- (Healthcare Sales & Marketing Network) -- Antares Pharma, Inc. (ATRS) today announced the appointment of Fred M. Powell to the position of Senior Vice President, Chief Financial Officer effective October 31, 2016. Mr. Powell ... Biopharmaceuticals, Personnel Antares Pharma, OTREXUP, methotrexate, rheumatoid arthritis (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - October 31, 2016 Category: Pharmaceuticals Source Type: news

Sanofi and Regeneron Receive Complete Response Letter from FDA for Sarilumab, an Investigational Treatment for Rheumatoid Arthritis
Paris and Tarrytown, N.Y. – October 28, 2016 – Sanofi and Regeneron Pharmaceuticals, Inc. today announced the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) regarding the Biologics License Applications (BLA) for... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - October 28, 2016 Category: Drugs & Pharmacology Source Type: news

Roche Gets Boost From FDA in Bid to Expand Uses for Actemra Roche Gets Boost From FDA in Bid to Expand Uses for Actemra
The U.S. Food and Drug Administration has granted breakthrough status to Roche ' s rheumatoid arthritis medication Actemra (tocilizumab) for giant cell arteritis, the Swiss drugmaker said, a step which could help it broaden applications for the medicine.Reuters Health Information (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - October 6, 2016 Category: Allergy & Immunology Tags: Rheumatology News Source Type: news

Roche gets boost from FDA in bid to expand uses for Actemra
ZURICH (Reuters) - The U.S. Food and Drug Administration has granted breakthrough status to Roche's rheumatoid arthritis medication Actemra for giant cell arteritis, the Swiss drugmaker said, a step which could help it broaden applications for the medicine. (Source: Reuters: Health)
Source: Reuters: Health - October 5, 2016 Category: Consumer Health News Tags: healthNews Source Type: news

New Building At Brigham And Women ’ s Could Revolutionize Health Care
BOSTON (CBS) – Last week WBZ reported on a new innovative building at Brigham and Women’s Hospital. That building opened its doors to patients Monday for the first time and Dr. Mallika Marshall was there to speak to one of those patients and his surgeons who helped make the building a reality. Plymouth’s George Svajian will never forget that one high school football game more than 50 years ago that destroyed his knee. “I went running down the sideline and as soon as put my leg down, the defensive back hit me right here and my knee felt like it went out,” recalls George. After years of crippling pain, Geor...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - October 3, 2016 Category: Consumer Health News Authors: Health – CBS Boston Tags: Health Local News Seen On WBZ-TV Syndicated Local Watch Listen Boston Brigham & Women's Hospital Dr. Mallika Marshall Source Type: news

Creepy Crawlie Therapy?
Discussion Humans are only one species among the multitudes that inhabit the earth. While many species are used by humans for food, clothing or shelter, as a higher evolved organism, humans are particularly aware of other species that move as they could be a potential predator or cause injury. This wariness is protective, but moving animal species can be domesticated (e.g. dogs, horses), farmed (e.g. cattle, goats) or harvested (e.g. fish, silk) for human use for food, clothing or shelter and also for medicinal use. Learning Point Medical leeches have been used since ancient times. The most commonly used leech is Hirudo me...
Source: PediatricEducation.org - October 3, 2016 Category: Pediatrics Authors: pediatriceducationmin Tags: Uncategorized Source Type: news

New discovery about cellular root of inflammation 'could aid arthritis treatment'
Scientists have made a new discovery about the key cellular processes that cause inflammation in the body. New research from the Trinity Biomedical Sciences Institute at Trinity College Dublin has been published in the leading scientific journal Cell, and could potentially open the door for new treatments for inflammatory conditions, including rheumatoidarthritis. How cells can cause inflammation To make this breakthrough, the team examined the function of macrophage cells, which play a key role in triggering the body's inflammation response to infection, before later putting the brakes on that initial response and rep...
Source: Arthritis Research UK - September 28, 2016 Category: Rheumatology Source Type: news

Janssen Submits Application Seeking Approval of Sirukumab in United States for Rheumatoid Arthritis
HORSHAM, Pa.--(BUSINESS WIRE) September 23, 2016 --Janssen Biotech, Inc. (Janssen) announced today the submission of a Biologics License Application (BLA) to the United States (U.S.) Food and Drug Administration (FDA) seeking approval of sirukumab... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - September 23, 2016 Category: Drugs & Pharmacology Source Type: news

FDA Approves Amgen's AMJEVITA ™ (Adalimumab-Atto) For Treatment Of Seven Inflammatory Diseases
First Regulatory Approval for Company's Biosimilar Portfolio First Biosimilar Adalimumab Approved by FDA THOUSAND OAKS, Calif., Sept. 23, 2016 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved AMJEVITA™ (adalimumab-atto) across all eligible indications of the reference product, Humira® (adalimumab). AMJEVITA is the first adalimumab biosimilar approved by the FDA and has been approved for the treatment of seven inflammatory diseases, including moderate-to-severe rheumatoid arthritis, moderate-to-severe polyarticular juvenile idiopathic arthritis, pso...
Source: Amgen News Release - September 23, 2016 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

The 10 Health Benefits Of Dogs (And One Health Risk)
1. Improve heart health Dogs don’t just fill your heart; they actually make it stronger. Studies show that having a canine companion is linked to lower blood pressure, reduced cholesterol, and decreased triglyceride levels, which contribute to better overall cardiovascular health and fewer heart attacks. What’s more, dog owners who do have heart attacks have better survival rates following the events. 2. Keep you fit and active Health experts recommend that adults get about 2 hours and 30 minutes worth of moderate exercise per week. Dog owners are way more likely to hit that goal. “People love to be outs...
Source: Healthy Living - The Huffington Post - September 23, 2016 Category: Consumer Health News Source Type: news

CBT 'can help chronic pain patients get better sleep'
People suffering chronicpain due to conditions such asarthritis could benefit from cognitive behavioural therapy (CBT) to help them get better sleep. This is according to a new study from the University of Warwick, which has demonstrated the impact that certain modes of thinking can have on sleeping habits among chronic pain patients, as well as highlighting ways this problem could be addressed. The impact of negative thinking on sleep Published in the Journal of ClinicalSleep Medicine, the research centred on the development of a new scale to measure beliefs about sleep and pain in long-term pain patients, while also exam...
Source: Arthritis Research UK - September 22, 2016 Category: Rheumatology Source Type: news

If an anti-TNF fails to treat RA, try a non-TNF biologic
Lower disease activity more likely in those on non-TNF biological than a second anti-TNF Related items fromOnMedica Breastfeeding may halve rheumatoid arthritis risk Rheumatoid arthritis heightens risk of dangerous leg and lung blood clots Drug for rheumatoid arthritis appears to have effect on severe eczema (Source: OnMedica Latest News)
Source: OnMedica Latest News - September 22, 2016 Category: UK Health Source Type: news

Arthritis drug may help with type of hair loss
Steven Reinberg, HealthDay News For people with a condition that causes disfiguring hair loss, a drug used for rheumatoid arthritis might regrow their hair, a new, small study suggests. (Source: Health News - UPI.com)
Source: Health News - UPI.com - September 22, 2016 Category: Consumer Health News Source Type: news

Hope for patients with hair loss: Arthritis drug spurs regrowth
Researchers at Yale and Stanford have provided the most conclusive evidence to date that a rheumatoid arthritis drug can also be used to grow hair on patients with a disease that causes disfiguring hair loss. (Source: Yale Science and Health News)
Source: Yale Science and Health News - September 22, 2016 Category: Universities & Medical Training Tags: Yale News Source Type: news

Non-TNF Drugs an Option for Patients With Unresponsive RA Non-TNF Drugs an Option for Patients With Unresponsive RA
Patients with rheumatoid arthritis that is not well controlled by one anti-TNF drug may experience better control with non-TNF-targeted therapy instead of a second anti-TNF drug, a new study showed.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 22, 2016 Category: Consumer Health News Tags: Rheumatology News Source Type: news

Arthritis Drug May Help With Type of Hair Loss
THURSDAY, Sept. 22, 2016 -- For people who suffer from a condition that causes disfiguring hair loss, a drug used for rheumatoid arthritis might regrow their hair, a new, small study suggests. Alopecia areata is an autoimmune disease that causes... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - September 22, 2016 Category: Journals (General) Source Type: news

Will Dixon awarded Professorship of Digital Epidemiology
Will Dixon, the Director of the Arthritis Research UK Centre for Epidemiology, has recently been promoted to the position of Professor of Digital Epidemiology by the University of Manchester. Congratulations Professor Dixon! As well as Professor Dixon’s post of Arthritis Research UK Centre Director, he is also project lead forCloudy with a chance of pain, which is the world's first smartphone-based study to investigate the association between pain and the weather. Participants candownload the app to their phone to record how they’re feeling, while local weather data is automatically collected using the phone's ...
Source: Arthritis Research UK - September 21, 2016 Category: Rheumatology Source Type: news

Going On Vacation Can Actually Change Your Gene Activity
(Reuters Health) - In a new study comparing a meditation retreat with just relaxing in the same locale, both options improved stress regulation, immune function and other cellular markers in the blood. Researchers measured gene activity, blood markers and reported wellbeing during the vacation and months afterward, and found a large and immediate “vacation effect” in all participants. For those who continued meditating, benefits were seen even 10 months later. “Vacation in a relaxing, resort-like environment takes you away from your day-to-day grind, which may be high stress in which your body is in a mor...
Source: Healthy Living - The Huffington Post - September 21, 2016 Category: Consumer Health News Source Type: news

Turmeric: Nature ’s Miracle Root for Disease
My friends Lelir and Westi in Bali don’t like to go to doctors. Nature is their pharmacy. You see, Lelir is a Balian. That means “herbal healer.” And Westi’s plantation is bursting with healing plants.  But one plant stands out above all the others. Lelir uses it to make a daily immune-boosting elixir as well as an anti-aging facial scrub. Balians use it as an antibiotic and for liver support. They boil it with milk and sugar to treat the common cold and allergies. Rural doctors make it into a paste with lime to ease sore joints. They make drinks to treat fevers and stomach pain. They mix it wi...
Source: Al Sears, MD Natural Remedies - September 20, 2016 Category: Complementary Medicine Authors: Al Sears Tags: Natural Cures Source Type: news

Lowering the Cut Point of the Classification Criteria for RA Lowering the Cut Point of the Classification Criteria for RA
Lowering the cut point of the 2010 classification criteria may help identify more patients with rheumatoid arthritis, a new study suggests.Rheumatology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 20, 2016 Category: Consumer Health News Tags: Rheumatology Journal Article Source Type: news

Discovery's Edge: The rheumatoid arthritis and heart disease connection
Physicians have long known that people with rheumatoid arthritis and other rheumatic conditions such as lupus are more likely to die at younger ages than are those without these conditions. Even with advances in treatment, the gap in life expectancy remains. No one knew why until 15 years ago. That ’s when researchers at Mayo Clinic [...] (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - September 19, 2016 Category: Databases & Libraries Source Type: news

Pfizer reports positive top-line results of Phase III REFLECTIONS B537-02 study of PF-06438179 to treat rheumatoid arthritis
Pfizer has announced that its confirmatory study REFLECTIONS B537-02, which evaluated the efficacy, safety, and immunogenicity of PF-06438179 (infliximab-Pfizer) compared to Remicade (infliximab), met its primary endpoint. (Source: Drug Development Technology)
Source: Drug Development Technology - September 18, 2016 Category: Pharmaceuticals Source Type: news

Diabetes: Medtronic touts JAMA study of closed-loop artificial pancreas
Medtronic (NYSE:MDT) said data from a study of its closed-loop hybrid artificial pancreas, published in the Journal of the American Medical Assn., showed that the system is safe and effectively maintained blood glucose levels within range in Type I diabetes patients age 14 and older. Results from the 3-month, 124-patient trial, also presented this week at the annual meeting of the European Assn. for the Study of Diabetes in Munich, had safety endpoints of the incidence of severe hypoglycemia and diabetic ketoacidosis, serious adverse events and device-related serious and unanticipated adverse events. Data from the study w...
Source: Mass Device - September 15, 2016 Category: Medical Equipment Authors: Brad Perriello Tags: Clinical Trials Diabetes Artificial pancreas Journal of the American Medical Assn. (JAMA) Medtronic Source Type: news

Prevention of Autoantibody-Positive Rheumatoid Arthritis Prevention of Autoantibody-Positive Rheumatoid Arthritis
A new review looks at the potential risk factors that may contribute to the development of rheumatoid arthritis and discusses preventive strategies.Rheumatology (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - September 15, 2016 Category: Allergy & Immunology Tags: Rheumatology Journal Article Source Type: news

Rising PSA Level in an Anxious Postprostatectomy Patient
A 66-year-old Caucasian man with a history of hypertension, hyperlipidemia, and rheumatoid arthritis was diagnosed with prostate cancer. (Source: CancerNetwork)
Source: CancerNetwork - September 15, 2016 Category: Cancer & Oncology Authors: Judd W. Moul, MD Robert Qi Tags: Case Studies Genitourinary Cancers Oncology Journal Prostate Cancer Source Type: news

Price Increases To Help Drug Hit $15 Billion In Sales
AbbVie’s Humira, used to treat rheumatoid arthritis and other autoimmune disorders, could reach $15 billion in annual sales, according to forecasts by the investment bank Leerink.* (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - September 14, 2016 Category: Pharmaceuticals Authors: Matthew Herper Source Type: news

Juvenile Idiopathic Arthritis (Juvenile Rheumatoid Arthritis)
Title: Juvenile Idiopathic Arthritis (Juvenile Rheumatoid Arthritis)Category: Diseases and ConditionsCreated: 12/31/1997 12:00:00 AMLast Editorial Review: 9/14/2016 12:00:00 AM (Source: MedicineNet Arthritis General)
Source: MedicineNet Arthritis General - September 14, 2016 Category: Rheumatology Source Type: news

Express Scripts Tries to Rein in Pricey Inflammatory Drugs Express Scripts Tries to Rein in Pricey Inflammatory Drugs
Express Scripts Holding, the largest manager of U.S. drug benefits, on Thursday launched a program aimed at tightening spending on drugs for pricey inflammatory conditions such as rheumatoid arthritis.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 9, 2016 Category: Consumer Health News Tags: Family Medicine/Primary Care News Source Type: news

Risk-benefit profile of statin therapy 'may be more positive than expected'
This study showed that providing an effective low-cost statin therapy to 10,000 patients for five years would prevent major cardiovascular events such as heart attacks, strokes and coronary artery bypasses in 1,000 people with preexisting vascular disease, as well as 500 people who are at increased risk but have not yet had a vascular event. By contrast, only 50 to 100 cases of symptomatic adverse events would be expected over the same period, as well as 50 to 100 new cases of diabetes, five cases of myopathy and between five and ten haemorrhagic strokes. Should statins be more widely used? Currently, about six million peo...
Source: Arthritis Research UK - September 8, 2016 Category: Rheumatology Source Type: news

Older rheumatoid arthritis patients 'must take special care over safety of biologics'
Elderly patients with rheumatoidarthritis may require special care when treated with biologics to manage potential safety issues arising from the use of thesedrugs. This is according to a new study led by Keio University School of Medicine in Japan, which has provided evidence that those over the age of 65 may be at greater risk of negative reactions when prescribed biologic therapies. More adverse events leading to treatment withdrawal In order to clarify the safety of biologic therapies in elderly patients withrheumatoid arthritis, the researchers analysed the performance of biologics in relation to age among a cohort of...
Source: Arthritis Research UK - September 6, 2016 Category: Rheumatology Source Type: news

Cardinal Health to pay up to $310m for Navidea ’ s LymphoSeek
Navidea (NYSE:NAVB) said today it inked a letter of intent with Cardinal Health (NYSE:CAH) to sell its Lymphoseek injection for up to $310 million. The sale includes all current FDA-approved indications, as well as future oncology diagnostic indications in North America and other related assets, Dublin, Ohio-based Navidea said. Through the deal, Navidea is slated to receive $80 million upon closing, with future considerations tied to annual sales of Lymphoseek and sales-based milestones. “This is a significant announcement for all of us at Navidea. This agreement with Cardinal Health will provide significant finan...
Source: Mass Device - September 6, 2016 Category: Medical Equipment Authors: Fink Densford Tags: Business/Financial News Diagnostics Mergers & Acquisitions Oncology Cardinal Health Navidea Biopharmaceuticals Source Type: news

I'm a Diabetic, Why is my Shoulder Frozen?
What Is Adhesive Capsulitis? Adhesive capsulitis is a painful, progressive loss of shoulder motion. The shoulder is usually stiff and will not move. This condition is called "frozen shoulder". When a patient presents with adhesive capsulitis, they are unable to move their arm up or turn it to either side either with or without assistance (passive/active range of motion). Typically adhesive capsulitis occurs in approximately 2% of the population and usually affects people 40-60 years of age. Frozen shoulder tends to occur more often in females. The loss of motion occurs due to inflammation, fibrosis, scarring and contractio...
Source: Healthy Living - The Huffington Post - September 6, 2016 Category: Consumer Health News Source Type: news

" At Your Service " Model to Help Pharma Be More Patient-Focused
In conclusion, Gerow stresses that this model fits a  21st century approach to doing business and the results speak for themselves. He recommends that companies carry out a pilot study to test the model, and is confident that they will find it is valued by doctors, lines up with their mission statements, and has a positive impact on the bottom line. “I f we can get closer to customers and provide something that they value while delivering great medicines to patients,” he asks “how could this not be the model of the future?”To learn more about the role of the service rep, download  " Patient-Centric Profitabilit...
Source: EyeForPharma - September 6, 2016 Category: Pharmaceuticals Authors: Nicola Davies Source Type: news

FDA Approves New Biological Drug for Rheumatoid Arthritis
Title: FDA Approves New Biological Drug for Rheumatoid ArthritisCategory: Health NewsCreated: 8/31/2016 12:00:00 AMLast Editorial Review: 9/1/2016 12:00:00 AM (Source: MedicineNet Arthritis General)
Source: MedicineNet Arthritis General - September 1, 2016 Category: Rheumatology Source Type: news

FDA approves new biological drug for rheumatoid arthritis
HealthDay News A new biological drug to treat rheumatoid arthritis and other inflammatory diseases has been approved by the U.S. Food and Drug Administration. (Source: Health News - UPI.com)
Source: Health News - UPI.com - August 31, 2016 Category: Consumer Health News Source Type: news

FDA Approves New Biological Drug for Rheumatoid Arthritis
WEDNESDAY, Aug. 31, 2016 -- A new biological drug to treat rheumatoid arthritis and other inflammatory diseases has been approved by the U.S. Food and Drug Administration. The drug Erelzi (etanercept-szzs) is a " biosimilar " to Enbrel (etanercept),... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - August 31, 2016 Category: Journals (General) Source Type: news